HC Wainwright reissued their buy rating on shares of TG Therapeutics (NASDAQ:TGTX – Free Report) in a research report sent to investors on Wednesday, Benzinga reports. HC Wainwright currently has a $49.00 price target on the biopharmaceutical company’s stock.
A number of other equities analysts have also recently issued reports on TGTX. The Goldman Sachs Group lifted their target price on shares of TG Therapeutics from $18.00 to $20.00 and gave the stock a neutral rating in a research report on Wednesday, August 7th. B. Riley raised their price objective on shares of TG Therapeutics from $29.00 to $34.00 and gave the stock a buy rating in a research note on Wednesday, August 7th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, TG Therapeutics presently has an average rating of Moderate Buy and a consensus target price of $31.83.
Get Our Latest Stock Report on TG Therapeutics
TG Therapeutics Stock Performance
TG Therapeutics (NASDAQ:TGTX – Get Free Report) last posted its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.08. The company had revenue of $73.47 million for the quarter, compared to analyst estimates of $65.92 million. TG Therapeutics had a return on equity of 57.73% and a net margin of 27.60%. TG Therapeutics’s revenue was up 357.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.34) earnings per share. As a group, equities analysts anticipate that TG Therapeutics will post 0.13 EPS for the current fiscal year.
Institutional Investors Weigh In On TG Therapeutics
Several hedge funds have recently modified their holdings of TGTX. Pingora Partners LLC purchased a new position in shares of TG Therapeutics during the fourth quarter valued at approximately $27,000. Ashton Thomas Private Wealth LLC acquired a new position in TG Therapeutics in the 2nd quarter valued at $35,000. DekaBank Deutsche Girozentrale purchased a new position in shares of TG Therapeutics during the 1st quarter worth $58,000. Lazard Asset Management LLC acquired a new stake in shares of TG Therapeutics during the first quarter worth $91,000. Finally, nVerses Capital LLC grew its position in shares of TG Therapeutics by 34.9% in the second quarter. nVerses Capital LLC now owns 5,800 shares of the biopharmaceutical company’s stock valued at $103,000 after purchasing an additional 1,500 shares during the period. 58.58% of the stock is owned by institutional investors and hedge funds.
About TG Therapeutics
TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
Further Reading
- Five stocks we like better than TG Therapeutics
- What is the Shanghai Stock Exchange Composite Index?
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- What is a Stock Market Index and How Do You Use Them?
- MarketBeat Week in Review – 9/16 – 9/20
- EV Stocks and How to Profit from Them
- Don’t Miss These 3 Retail Stocks for Fall Gains
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.